Skip to main content

Advertisement

SpringerLink
Log in

Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

S-1 is a fourth-generation oral fluoropyrimidine that was developed to mimic the effects achieved with protracted continuous infusion of 5-fluorouracil (5-FU). This phase II study evaluated the efficacy and safety of S-1 salvage chemotherapy in patients with paclitaxel- and cisplatin-refractory gastric cancer. The primary end point was progression-free survival; secondary end points were overall survival, safety, and clinical benefit.

Methods

Patients were eligible for the study if they had histologically documented gastric adenocarcinoma previously treated with paclitaxel and cisplatin, age ≥ 18 years, Eastern Clinical Oncology Group performance status ≤2, adequate organ function, and no evidence of gastrointestinal obstruction or passage disturbance. Patients were treated with a dose of S-1 based on body surface area (BSA) as follows: BSA < 1.25 m2, 80 mg/day; 1.25 ≤ BSA < 1.5 m2, 100 mg/day; BSA ≥ 1.5 m2, 120 mg/day. The total dose was divided in two and administered twice daily for 4 weeks followed by a 2-week rest period.

Results

Of the 53 patients enrolled in this study, 49 were evaluable. A total of 190 chemotherapy cycles were administered, and the median number of cycles was 2. Five patients (9.4%) had a partial response, and 18 (34%) had stable disease. Median progression-free survival and overall survival were 4.9 and 10.4 months, respectively. Grade 3/4 hematological toxicities included neutropenia in six patients (11%) but no cases of febrile neutropenia were found. Most of the non-hematological toxicities were diarrhea, asthenia, and mucositis, but none reached grade 3 or grade 4 in severity. Improvement of pain was observed in 17 patients (32.1%).

Conclusions

S-1 monotherapy provides active and safe salvage chemotherapy for patients with advanced gastric cancer who have been previously treated with paclitaxel and cisplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1–9

    Article  PubMed  Google Scholar 

  2. Shin HR, Jung KW, Won YJ, Park JG (2004) 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 36:103–114

    Article  PubMed  Google Scholar 

  3. Alberts SR, Cervantes A, van de Velde CJ (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14:31–36

    Google Scholar 

  4. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H (1994) A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5:609–616

    PubMed  CAS  Google Scholar 

  5. Lacave AJ, Barón FJ, Antón LM, Estrada E, De Sande LM, Palacio I, Esteban E, Gracia JM, Buesa JM, Fernández OA (1991) Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 2:751–754

    PubMed  CAS  Google Scholar 

  6. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Bognel C, Lasser P, Ychou M, Elias D (1994) Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 30A:1263–1269

    Article  PubMed  CAS  Google Scholar 

  7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24:4991–4997

    Article  PubMed  CAS  Google Scholar 

  8. Hwang J, Cho SH, Shim HJ, Lee SR, Ahn JS, Yang DH, Kim YK, Lee JJ, Kim HJ, Chung IJ (2008) Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. J Korean Med Sci 23:586–591

    Article  PubMed  CAS  Google Scholar 

  9. Kornek GV, Raderer M, Schüll B, Fiebiger W, Gedlicka C, Lenauer A, Depisch D, Schneeweiss B, Lang F, Scheithauer W (2002) Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer 86:1858–1863

    Article  PubMed  CAS  Google Scholar 

  10. Hsu Y, Sood AK, Sorosky JI (2004) Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer. Am J Clin Oncol 27:14–18

    Article  PubMed  CAS  Google Scholar 

  11. Park SH, Lee WK, Chung M, Lee Y, Han SH, Bang SM, Cho EK, Shin DB, Lee JH (2006) Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs 17:225–229

    Article  PubMed  CAS  Google Scholar 

  12. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715–1720

    Article  PubMed  CAS  Google Scholar 

  13. Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58:191–197

    Article  PubMed  CAS  Google Scholar 

  14. Jeung HC, Rha SY, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC (2007) A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer 20:458–463

    Article  CAS  Google Scholar 

  15. Takahashi I, Kakeji Y, Emi Y, Sakurai M, Yonemura Y, Kimura Y, Maehara Y (2003) S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects. Gastric Cancer 6:28–33

    Article  PubMed  Google Scholar 

  16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  17. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10:425–433

    Google Scholar 

  18. Lerner A, Gonin R, Steele GD Jr, Mayer RJ (1992) Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 10:536–540

    PubMed  CAS  Google Scholar 

  19. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  20. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37–41

    Article  PubMed  CAS  Google Scholar 

  21. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591

    PubMed  Google Scholar 

  22. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163–168

    Article  PubMed  CAS  Google Scholar 

  23. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G (1998) Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 9:307–310

    Article  PubMed  CAS  Google Scholar 

  24. Stathopoulos GP, Rigatos SK, Fountzilas G, Polyzos A, Stathopoulos JG (2002) Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study. Oncol Rep 9:89–92

    PubMed  CAS  Google Scholar 

  25. Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, Catalano G, Battelli N, Cascinu S (2000) A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 11:1263–1266

    Article  PubMed  CAS  Google Scholar 

  26. Schmid KE, Kornek GV, Schüll B, Raderer M, Lenauer A, Depisch D, Lang F, Scheithauer W (2003) Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie 26:255–258

    Article  PubMed  CAS  Google Scholar 

  27. Giuliani F, Gebbia V, De Vita F, Maiello E, Di Bisceglie M, Catalano G, Gebbia N, Colucci G (2003) Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res 23:4219–4222

    PubMed  CAS  Google Scholar 

  28. Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, Kim BS, Kim M, Chun YJ, Lee JS, Kang YK (2008) A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 61:631–637

    Article  PubMed  CAS  Google Scholar 

  29. Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Lee SS, Lee JS, Kang YK (2008) Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol 31:151–156

    Article  PubMed  CAS  Google Scholar 

  30. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548–557

    Article  PubMed  CAS  Google Scholar 

  31. Jeung HC, Rha SY, Kim HK, Lim HY, Kim S, Kim SY, Gong SJ, Park CH, Ahn JB, Noh SH, Chung HC (2007) Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. Oncologist 12:543–554

    Article  PubMed  CAS  Google Scholar 

  32. Schöffski P (2004) The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15:85–106

    Article  PubMed  Google Scholar 

  33. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T (1999) An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57:202–210

    Article  PubMed  CAS  Google Scholar 

  34. Nagashima F, Ohtsu A, Yoshida S, Ito K (2005) Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 8:6–11

    Article  PubMed  Google Scholar 

  35. Kobayashi O, Konishi K, Kanari M, Cho H, Yoshikawa T, Tsuburaya A, Sairenji M, Motohashi H (2002) Unusual survival for more than 2 years with peritoneal metastases of gastric cancer. Gastric Cancer 5:47–50

    Article  PubMed  Google Scholar 

  36. Fujitani K, Tsujinaka T, Hirao M (2003) Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding. Hepatogastroenterology 50:889–892

    PubMed  Google Scholar 

  37. Osugi H, Takada N, Takemura M, Kaseno S, Lee S, Ueno M, Tanaka Y, Fukuhara K, Fujiwara Y, Kinoshita H (2002) Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination. Oncol Rep 9:811–815

    PubMed  CAS  Google Scholar 

  38. Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S, Monden M (2003) Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer. Gastric Cancer 6:13–18

    Article  PubMed  Google Scholar 

  39. Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, Kim NK (2003) Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 14:383–387

    Article  PubMed  CAS  Google Scholar 

  40. Kim SG, Oh SY, Kwon HC, Lee S, Kim JH, Kim SH, Kim HJ (2007) A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol 37:744–749

    Article  PubMed  Google Scholar 

  41. Ueda S, Hironaka S, Boku N, Fukutomi A, Yoshino T, Onozawa Y (2006) Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer. Gastric Cancer 9:203–207

    Article  PubMed  CAS  Google Scholar 

  42. Park SH, Choi EY, Bang SM, Cho EK, Lee JH, Shin DB, Ki Lee W, Chung M (2005) Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anticancer Drugs 16:621–625

    Article  PubMed  CAS  Google Scholar 

  43. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K (2005) Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane and cisplatin refractory, metastatic gastric cancer. Br J Cancer 92:1850–1854

    Article  PubMed  CAS  Google Scholar 

  44. Sencan O, Buyukcelik A, Yalcin B, Boruban MC, Akbulut H, Demirkazik A, Senler FC, Onur H, Icli F (2008) The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. Eur J Cancer Care 17:26–32

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hemato-Oncology, Department of Internal Medicine, Center for Biomedical Human Resources, Chonnam National University Medical School, Kwangju, Korea

    Sung-Ji Lee, Sang-Hee Cho, Ju-Young Yoon, Jun-Eul Hwang, Woo-Kyun Bae, Hyun-Jeong Shim & Ik-Joo Chung

  2. The Brain Korea 21 Project, Center for Biomedical Human Resources, Chonnam National University Medical School, Kwangju, Korea

    Ik-Joo Chung

  3. Department of Internal Medicine, Chonnam National University Hwasun Hospital, Jeollanamdo, 519-809, Korea

    Ik-Joo Chung

Authors
  1. Sung-Ji Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang-Hee Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ju-Young Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun-Eul Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Woo-Kyun Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hyun-Jeong Shim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ik-Joo Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ik-Joo Chung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, SJ., Cho, SH., Yoon, JY. et al. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. Cancer Chemother Pharmacol 65, 159–166 (2009). https://doi.org/10.1007/s00280-009-1019-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-009-1019-4

Keywords

Search

Navigation